FierceBiotech ٨ يناير ٢٠٢٦ Lilly links up with InduPro in next-gen cancer treatment deal worth up to $950M
Endpoints News ٢٢ ديسمبر ٢٠٢٥ Aktis Oncology files for IPO to fund Lilly-partnered radiopharma pipeline
BioPharma Dive ١٨ ديسمبر ٢٠٢٥ Lilly obesity pill, headed for quick FDA review, hits mark in ‘maintenance’ trial
Endpoints News ١٨ ديسمبر ٢٠٢٥ Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance setting
FierceBiotech ١١ ديسمبر ٢٠٢٥ Lilly's obesity triple threat smashes efficacy expectations in phase 3 but proves intolerable for some
Endpoints News ١١ ديسمبر ٢٠٢٥ Lilly’s triple agonist posts strongest weight loss data yet, unusual skin side effect also reported